Scynexis (SCYX) Asset Writedowns and Impairment (2014 - 2016)

Scynexis (SCYX) reported Asset Writedowns and Impairment of $111000.0 for Q1 2016, down 91.78% quarter-over-quarter from $1.3 million in Q2 2015.

Scynexis (SCYX) Asset Writedowns and Impairment (2014 - 2016) Analysis & Trends

Scynexis has reported Asset Writedowns and Impairment for 3 years, with the latest figure at $111000.0 in Q1 2016.

For the quarter ending Q1 2016, Asset Writedowns and Impairment changed N/A year-over-year to $111000.0; the trailing twelve-month figure through Dec 2016 stood at $111000.0 (down 91.45% YoY), and the FY2023 full-year result was $14.6 million, changed N/A from the prior year.
Asset Writedowns and Impairment for Q1 2016 stood at $111000.0, down from $1.3 million in the prior quarter.
The five-year high for Asset Writedowns and Impairment was $1.3 million in Q2 2015, with the low at -$51000.0 in Q4 2014.
Historically, Asset Writedowns and Impairment has averaged $470000.0 across 3 years, with a median of $111000.0 in 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Teva Pharmaceutical Industries	39.72 Bn	35.98 Bn	1.97 Bn
2	Zoetis	34.61 Bn	32.67 Bn	1.62 Bn
3	United Therapeutics	24.07 Bn	21.91 Bn	648.10 Mn
4	Aurora Cannabis	16.98 Bn	16.91 Bn	33.43 Mn
5	Neurocrine Biosciences	16.64 Bn	15.32 Bn	800.70 Mn
6	Elanco Animal Health	12.19 Bn	11.76 Bn	785.00 Mn
7	Alkermes	7.37 Bn	6.86 Bn	-116.06 Mn
8	Hims & Hers Health	6.62 Bn	5.87 Bn	396.79 Mn
9	Lantheus Holdings	6.47 Bn	5.97 Bn	230.92 Mn
10	Scynexis	225.23 Mn	165.97 Mn	-

Download Data